Cypsedo

(Cipepofol)

ApprovedSmall molecule

HHaisco-USA Pharmaceuticals, Inc.

Cypsedo is one of 12 small molecule programs targeting General Anesthesia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

General AnesthesiaRecruiting

General AnesthesiaApproved

Recruiting

Competition

Competitive Landscape

18 competitors in General Anesthesia

#DrugCompanyPhaseTrials

Anerem

AAcacia Pharma Ltd

Approved

7 2

Cypsedo

HHaisco-USA Pharmaceuticals, Inc.

Approved

1 3

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

1 4

Amidate

Pfizer

Phase 1

2 5

Robinul

Jazz Pharmaceuticals

Preclinical

1 6

Carbocaine

Pfizer

Preclinical

1 7

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Preclinical

2 8

Dexmedetomidine Hydrochloride

Pfizer

Preclinical

2 9

Opioid

Johnson & Johnson

Preclinical

1 10

General Anesthetic

IInstitutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

General Anesthesia1 trial

A Study to Evaluate the Accuracy of aTCI Model of Cipepofol in Patients With General Anesthesia During Elective Surgery

Recruiting· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 4·NCT06740201·40 enrolled

Efficacy and Safety1 trial

A Multicenter, Open, Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Cipepofol Injection for General Anesthesia in Pediatric Patients Undergoing Elective Surgery

Completed· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 3·NCT06391931·190 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 27, 2026

CYPSEDO

NDA NDA220482

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cipepofol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cipepofol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cipepofol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA220482). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Cypsedo. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Haisco-USA Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHaisco-USA Pharmaceuticals, Inc.

Patent Landscape[5]

Patent Cliff

May 6, 2034

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10729666May 6, 2034

9517988May 6, 2034

Cypsedo

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

General Anesthesia1 trial

Efficacy and Safety1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News